Skip to main content
Top
Published in: BMC Nephrology 1/2004

Open Access 01-12-2004 | Research article

Determination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis: an in-vitrostudy

Authors: Harold J Manley, Darren W Grabe

Published in: BMC Nephrology | Issue 1/2004

Login to get access

Abstract

Background

Intravenous iron is typically administered during the hemodialysis (HD) procedure. HD patients may be prescribed high-flux (HF) or high-efficiency (HE) dialysis membranes. The extent of iron sucrose and iron dextran removal by HD using HF or HE membranes and by ultrafiltration rate (UFR) is unknown.

Methods

Two in vitro HD systems were designed and constructed to determine the dialyzabiltiy of iron from a simulated blood system (SBS) containing 100 mg iron sucrose or iron dextran (system A) or 1000 mg iron sucrose (system B). Both in vitro systems utilized a 6-L closed-loop SBS system that was subject to 4 different HD conditions conducted over 4 hours: HE membrane + 0 ml/hr UFR; HE membrane + 500 ml/hr UFR; HF membrane + 0 ml/hr UFR; HF membrane + 500 ml/hr UFR. Blood flow and dialysate flow rates were 500 ml/min and 800 ml/min, respectively. The dialysate compartment was a 192-L open system for system A and a 6-L closed-loop system for system B. Samples from the SBS and dialysate compartments were taken at various time points and iron elimination rate and HD clearance was determined. Iron removal from the SBS > 15% was considered clinically significant.

Results

The greatest percentage removal from the SBS was 13.5% and -0.03% utilizing system A and B, respectively. Iron sucrose and iron dextran dialysate concentration was below the lower limits of assay (< 2 ppm) for system A. Dialysate recovery of iron was negligible: 0 – 5.4 mg system A and 5.47 – 23.59 mg for system B. Dialyzer type or UFR did not affect iron removal.

Conclusion

HF or HE dialysis membranes do not remove clinically significant amounts of iron sucrose or dextran formulations over a 4-hour HD session. This effect remained constant even controlling for UFR up to 500 ml/hour. Therefore, iron sucrose and iron dextran are not dialyzed by HE or HF dialysis membranes irrespective of UFR.
Literature
1.
go back to reference NKF-K/DOQI: Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 37 (1 Suppl 1): S182-238. NKF-K/DOQI: Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 37 (1 Suppl 1): S182-238.
2.
go back to reference Kumpf VJ, Holland EG: Parenteral iron dextran therapy. DICP Ann Pharmacother. 1990, 24: 162-166. Kumpf VJ, Holland EG: Parenteral iron dextran therapy. DICP Ann Pharmacother. 1990, 24: 162-166.
3.
go back to reference Fishbane S, Kowalski EA: The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial. 2000, 13: 381-4. 10.1046/j.1525-139x.2000.00104.x.CrossRefPubMed Fishbane S, Kowalski EA: The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial. 2000, 13: 381-4. 10.1046/j.1525-139x.2000.00104.x.CrossRefPubMed
4.
go back to reference Venofer (iron sucrose injection) package insert. American Regent Laboratories, Inc., Shirley, New York, USA. 2000 Venofer (iron sucrose injection) package insert. American Regent Laboratories, Inc., Shirley, New York, USA. 2000
5.
go back to reference Lawrence R: Development and comparison of iron dextran products. PDA J Pharm Sci Technol. 1998, 52: 190-197.PubMed Lawrence R: Development and comparison of iron dextran products. PDA J Pharm Sci Technol. 1998, 52: 190-197.PubMed
6.
go back to reference Manual MA, Stewark WK, St Clair Neill GD, Hutchinson F: Loss of iron-dextran through cupraphane membrane of a disposable coil dialyser. Nephron. 1972, 9: 94-98.CrossRef Manual MA, Stewark WK, St Clair Neill GD, Hutchinson F: Loss of iron-dextran through cupraphane membrane of a disposable coil dialyser. Nephron. 1972, 9: 94-98.CrossRef
7.
go back to reference Hatton RC, Portales IT, Finlay A, Ross EA: Removal of iron dextran by hemodialysis: an in vitro study. Am J Kidney Dis. 1995, 26: 327-330.CrossRefPubMed Hatton RC, Portales IT, Finlay A, Ross EA: Removal of iron dextran by hemodialysis: an in vitro study. Am J Kidney Dis. 1995, 26: 327-330.CrossRefPubMed
8.
go back to reference Bailie GR, Handa JJ, Tang L, Low CL, Eisele G: Minimal removal of iron-dextran by conventional haemodialysis. An in vivo study. Clin Drug Invest. 1997, 14: 12-15.CrossRef Bailie GR, Handa JJ, Tang L, Low CL, Eisele G: Minimal removal of iron-dextran by conventional haemodialysis. An in vivo study. Clin Drug Invest. 1997, 14: 12-15.CrossRef
9.
go back to reference Bailie GR, Johnson CA, Mason NA: Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis. 2000, 35: 1-12.CrossRefPubMed Bailie GR, Johnson CA, Mason NA: Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis. 2000, 35: 1-12.CrossRefPubMed
10.
go back to reference Curtis J: Module IV: Hemodialysis devices. In: Core curriculum for the dialysis technician. Amgen Inc. Thousand Oaks, CA, 2 Curtis J: Module IV: Hemodialysis devices. In: Core curriculum for the dialysis technician. Amgen Inc. Thousand Oaks, CA, 2
11.
go back to reference Manley HJ, Grabe DW, Norcross M, Bailie GR: The stability of iron dextran (Dexferrum) in peritoneal dialysis solution. Perit Dial Int. 1998, 18: 538-540.PubMed Manley HJ, Grabe DW, Norcross M, Bailie GR: The stability of iron dextran (Dexferrum) in peritoneal dialysis solution. Perit Dial Int. 1998, 18: 538-540.PubMed
12.
go back to reference Macdougall IC, Chandler G, Armstrong A, Breen C, Harchowal J, Cavil : Characterization of iron availability from three different IV iron preparations in dialysis patients. J Amer Soc Nephrol. 1997, 8: 221A- Macdougall IC, Chandler G, Armstrong A, Breen C, Harchowal J, Cavil : Characterization of iron availability from three different IV iron preparations in dialysis patients. J Amer Soc Nephrol. 1997, 8: 221A-
Metadata
Title
Determination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis: an in-vitrostudy
Authors
Harold J Manley
Darren W Grabe
Publication date
01-12-2004
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2004
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-5-1

Other articles of this Issue 1/2004

BMC Nephrology 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.